- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03460977
PF-06821497 Behandling av residiverende/refraktær SCLC, kastrasjonsresistent prostatakreft og follikulært lymfom
EN FASE I DOSESEKALASJON OG UTVIDET KOHORTSTUDIE AV PF-06821497 I BEHANDLING AV VOKSNE PASIENTER MED RESIPPERT/REFRAKTORISK SMÅCELLET LUNGEKREFT (SCLC), KASTRASJONSRESISTENT PROSTATAKANCER (FHOLIPCULAR)
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-post: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
-
Haskovo, Bulgaria, 6300
- Avsluttet
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85719
- Aktiv, ikke rekrutterende
- Banner-University Medical Center Tucson
-
Tucson, Arizona, Forente stater, 85719
- Aktiv, ikke rekrutterende
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, Forente stater, 85724
- Aktiv, ikke rekrutterende
- The University of Arizona Cancer Center
-
Tucson, Arizona, Forente stater, 85741
- Avsluttet
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, Forente stater, 92801
- Aktiv, ikke rekrutterende
- Pacific Cancer Medical Center INC
-
Duarte, California, Forente stater, 91010
- Aktiv, ikke rekrutterende
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, Forente stater, 91010
- Aktiv, ikke rekrutterende
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, Forente stater, 06856
- Aktiv, ikke rekrutterende
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, Forente stater, 66205
- Aktiv, ikke rekrutterende
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, Forente stater, 66205
- Aktiv, ikke rekrutterende
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, Forente stater, 66160
- Aktiv, ikke rekrutterende
- The University of Kansas Hospital
-
Kansas City, Kansas, Forente stater, 66160
- Aktiv, ikke rekrutterende
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, Forente stater, 66211
- Aktiv, ikke rekrutterende
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, Forente stater, 66205
- Aktiv, ikke rekrutterende
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Aktiv, ikke rekrutterende
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, Forente stater, 40202
- Aktiv, ikke rekrutterende
- Norton Hospital
-
Louisville, Kentucky, Forente stater, 40202
- Aktiv, ikke rekrutterende
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, Forente stater, 20850
- Avsluttet
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Aktiv, ikke rekrutterende
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02115
- Aktiv, ikke rekrutterende
- Brigham and Women's Hospital
-
Newton, Massachusetts, Forente stater, 02459
- Aktiv, ikke rekrutterende
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68130
- Rekruttering
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Aktiv, ikke rekrutterende
- Hackensack University Medical Center
-
Hackensack, New Jersey, Forente stater, 07601
- Aktiv, ikke rekrutterende
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Rekruttering
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Rekruttering
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Forente stater, 78705
- Avsluttet
- Texas Oncology - Austin Midtown
-
Dallas, Texas, Forente stater, 75390
- Aktiv, ikke rekrutterende
- UT Southwestern Medical Center
-
Dallas, Texas, Forente stater, 75390
- Aktiv, ikke rekrutterende
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, Forente stater, 75390
- Aktiv, ikke rekrutterende
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, Forente stater, 75390
- Aktiv, ikke rekrutterende
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, Forente stater, 75063
- Avsluttet
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, Forente stater, 75063
- Avsluttet
- US Oncology Investigational Products Center
-
Irving, Texas, Forente stater, 75039
- Rekruttering
- NEXT Dallas
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- NEXT Oncology
-
San Antonio, Texas, Forente stater, 78240
- Aktiv, ikke rekrutterende
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Aktiv, ikke rekrutterende
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, Forente stater, 98362
- Aktiv, ikke rekrutterende
- Olympic Medical Center
-
Poulsbo, Washington, Forente stater, 98370
- Aktiv, ikke rekrutterende
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, Forente stater, 98109
- Aktiv, ikke rekrutterende
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Forente stater, 98109
- Aktiv, ikke rekrutterende
- University of Washington Medical Center
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Aktiv, ikke rekrutterende
- National Cancer Center Hospital East
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510120
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, Kina, 410013
- Aktiv, ikke rekrutterende
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210009
- Aktiv, ikke rekrutterende
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, Kina, 210008
- Aktiv, ikke rekrutterende
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, Kina, 325000
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Bydgoszcz, Polen, 85-048
- Har ikke rekruttert ennå
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, Polen, 75-581
- Aktiv, ikke rekrutterende
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, Polen, 30-348
- Rekruttering
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, Polen, 35-326
- Aktiv, ikke rekrutterende
- Centrum Medyczne MEDYK
-
Warsaw, Polen, 02-781
- Aktiv, ikke rekrutterende
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
-
Moscow, Russland, 117186
- Aktiv, ikke rekrutterende
- LLC "Neyro-klinika"
-
Moscow, Russland, 125284
- Avsluttet
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, Russland, 129301
- Avsluttet
- SBHI of Moscow City Clinical Hospital
-
Omsk, Russland, 644013
- Avsluttet
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, Russland, 197341
- Avsluttet
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, Russland, 197758
- Avsluttet
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, Russland, 198255
- Avsluttet
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, Russland, 150054
- Avsluttet
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, Russland, 196603
- Aktiv, ikke rekrutterende
- Private Medical Institution "Euromedservice"
-
-
-
-
-
Barcelona, Spania, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spania, 08036
- Rekruttering
- Hospital Clinic de Barcelona
-
Barcelona, Spania, 08023
- Rekruttering
- Hospital Quironsalud Barcelona
-
Madrid, Spania, 28034
- Rekruttering
- Hospital Universitario Ramon y Cajal
-
Madrid, Spania, 28040
- Rekruttering
- Hospital Clinico San Carlos
-
Madrid, Spania, 28050
- Rekruttering
- Hospital Universitario HM Sanchinarro
-
Madrid, Spania, 28040
- Rekruttering
- H.U. Fundación Jiménez Díaz
-
Madrid, Spania, 28041
- Rekruttering
- Hospital Universitario 12 De Octubre
-
Málaga, Spania, 29010
- Rekruttering
- Hospital Universitario Virgen de la Victoria
-
Valencia, Spania, 46026
- Aktiv, ikke rekrutterende
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, Spania, 08908
- Aktiv, ikke rekrutterende
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, Spania, 12002
- Aktiv, ikke rekrutterende
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spania, 28223
- Rekruttering
- Hospital Quironsalud Madrid
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Sør -Korea, 13620
- Rekruttering
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], Sør -Korea, 03080
- Aktiv, ikke rekrutterende
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Sør -Korea, 07985
- Aktiv, ikke rekrutterende
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Sør -Korea, 03722
- Aktiv, ikke rekrutterende
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, Sør -Korea, 35015
- Aktiv, ikke rekrutterende
- Chungnam national university hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
Andre navn:
|
|
Eksperimentell: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
Andre navn:
|
|
Eksperimentell: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
Andre navn:
|
|
Eksperimentell: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
Andre navn:
Oral continuous
Andre navn:
|
|
Eksperimentell: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
Andre navn:
Oral continuous
Andre navn:
|
|
Eksperimentell: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
Andre navn:
|
|
Eksperimentell: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
Andre navn:
|
|
Eksperimentell: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
Andre navn:
Oral continuous
Andre navn:
|
|
Eksperimentell: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Andre navn:
Oral continuous
Andre navn:
|
|
Eksperimentell: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Andre navn:
Oral continuous
Andre navn:
Oral solution
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Tidsramme: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
Tidsramme: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
Tidsramme: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
Tidsramme: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
Tidsramme: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Tidsramme: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Tidsramme: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
Tidsramme: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
Tidsramme: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Tidsramme: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdomsattributter
- Sykdommer i immunsystemet
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Patologiske tilstander, tegn og symptomer
- Hemic og lymfatiske sykdommer
- Tilbakefall
- Småcellet lungekarsinom
- Lymfom, follikulær
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Triazoler
- Piperazines
- Itrakonazol
- Enzalutamid
- PF06821497
Andre studie-ID-numre
- C2321001
- 2023-509179-18-00 (Registeridentifikator: CTIS (EU))
- EZH2 (Annen identifikator: Alias Study Number)
- 2023 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .